International Aids Vaccine Initiative

🇰🇪Kenya

Country: 🇰🇪Kenya

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: -

Website: http://www.iavi.org

Clinical Trials

A Phase 1 Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and with HIV

Phase 1

Not yet recruiting

Conditions: HIV

Interventions: Drug: GRAdHIVNE1 Vaccine
Other: Placebo

First Posted Date: 2024-09-27

Last Posted Date: 2024-09-27

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 120

Registration Number: NCT06617091

Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living With HIV (PLWH) in Africa

Early Phase 1

Not yet recruiting

Conditions: HIV

Interventions: Drug: Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)

First Posted Date: 2024-06-07

Last Posted Date: 2024-06-07

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 40

Registration Number: NCT06449196

Locations: 🇿🇲
Center For Family Health Research in Zambia (CFHRZ), Lusaka, Zambia
🇺🇬
Uganda Virus Research Institute (UVRI), Entebbe, Uganda

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.

Phase 2

Not yet recruiting

Conditions: Tuberculosis (TB)

Interventions: Biological: MTBVAC
Biological: Placebo

First Posted Date: 2024-02-22

Last Posted Date: 2024-02-22

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 4300

Registration Number: NCT06272812

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

Phase 1

Conditions: Hiv

Interventions: Biological: BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage

First Posted Date: 2023-08-09

Last Posted Date: 2024-06-11

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 8

Registration Number: NCT05983874

Locations: 🇳🇱
The Amsterdam University Medical Centers, Amsterdam, Netherlands

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

Phase 2

Recruiting

Conditions: Lassa Fever

Interventions: Drug: Day 1 Lower Dose (2×106 pfu)
Drug: Day 1 Higher Dose (1×107 pfu)
Drug: Placebo

First Posted Date: 2023-05-22

Last Posted Date: 2024-03-18

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 612

Registration Number: NCT05868733

Locations: 🇬🇭
Noguchi Memorial Institute for Medical Research (NMIMR), Accra, Ghana
🇳🇬
Walter Reed Program - Nigeria, Wuse, Nigeria
🇱🇷
PREVAIL_ John F. Kennedy Medical Center (JFK), Monrovia, Liberia

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate

Phase 1

Not yet recruiting

Conditions: Hiv

Interventions: Drug: BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)

First Posted Date: 2023-05-18

Last Posted Date: 2023-05-18

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 14

Registration Number: NCT05863585

Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

Phase 1

Completed

Conditions: Ebola Sudan Virus Disease

Interventions: Drug: rVSV∆G-SEBOV-GP Vaccine or Placebo

First Posted Date: 2023-02-13

Last Posted Date: 2024-11-06

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 36

Registration Number: NCT05724472

Locations: 🇺🇸
Benchmark Research, Austin, Texas, United States
🇺🇸
Clinical Trials of Texas, San Antonio, Texas, United States

A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)

Phase 1

Active, not recruiting

Conditions: HIV-1-infection

Interventions: Biological: eOD-GT8 60mer mRNA Vaccine (100µg)

First Posted Date: 2022-06-10

Last Posted Date: 2023-03-10

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 18

Registration Number: NCT05414786

Locations: 🇿🇦
Aurum Tembisa Clinical Research Centre, Johannesburg, South Africa
🇷🇼
Center for Family Health Research, Kigali, Rwanda

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Phase 1

Active, not recruiting

Conditions: Hiv

Interventions: Biological: Core-g28v2 60mer mRNA Vaccine
Biological: eOD-GT8 60mer mRNA Vaccine

First Posted Date: 2021-08-11

Last Posted Date: 2024-05-01

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 56

Registration Number: NCT05001373

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 1 locations

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

Phase 1

Active, not recruiting

Conditions: Lassa Fever
Lassa Virus Infection

Interventions: Drug: rVSV∆G-LASV-GPC
Other: Placebo/Diluent

First Posted Date: 2021-03-11

Last Posted Date: 2024-01-18

Lead Sponsor: International AIDS Vaccine Initiative

Target Recruit Count: 114

Registration Number: NCT04794218

Locations: 🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸
Brigham and Women's Hospital, Brookline, Massachusetts, United States
🇱🇷
Redemption Hospital, New Kru Town, Greater Monrovia, Liberia

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy